Makeda Semret
- Feb 10, 2021
- 1 min read

Check out updates to COVID-19 management guideline!

Our guideline working group has reviewed latest evidence and recommends therapeutic anticoagulation (instead of prophylactic) for mild and moderate COVID-19. This is based on review of latest evidence from 3 international trials, demonstrating marked benefit (net benefit in terms of organ-support free days, irrespective of D-dimer levels). No benefit (and possible harm) for severe COVID-19. Endorsed by MUHC P&T committee!

Recent Posts

See All

Occupational exposure prophylaxy guidelines

ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar

Correction in Antifungal prophylaxis for high-risk (immunocompromised)

Correction made for Heart transplant and Lung transplant recipients: both anti-mold AND anti-PJP prophylaxis recommended.